Emcure Pharmaceuticals Reports Robust Q2FY26 Performance with 13% Revenue Growth and 25% Profit After Tax Growth
Ahmedabad, November 13: Emcure Pharmaceuticals (BSE:544210, NSE: EMCURE) today announced its consolidated financial results for the quarter ended September 30th, 2025. The quarter saw strong performance from both Domestic and International businesses. Domestic business grew 10.6% led by strong performance across all our key therapies and aided by new initiatives. Domestic business remains a key…
